New combo targets DNA repair to fight pancreatic cancer
NCT ID NCT01489865
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new combination of drugs (ABT-888 plus chemotherapy) in 64 people with pancreatic cancer that had spread. The goal was to see if adding ABT-888, which blocks cancer cells from fixing DNA damage, could make chemotherapy work better and shrink tumors. The study was for patients with certain genetic mutations linked to breast or ovarian cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Smart drug delivers chemo directly to pancreatic cancer cells
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia